全球避孕药具市场规模、份额、趋势和成长分析报告（2026-2034年）

预计避孕药具市场将从 2025 年的 297.1 亿美元成长到 2034 年的 532.2 亿美元，2026 年至 2034 年的复合年增长率为 6.69%。

在全球计划生育意识增强、生殖健康促进措施以及政府支持的人口控制计画的推动下，全球避孕市场稳步增长。口服避孕药、保险套、子宫内避孕器（IUD）、注射和植入产品在已开发市场和新兴市场均已广泛应用。性教育的普及和医疗保健服务的改善进一步促进了避孕产品的使用。

成长要素包括女性劳动参与率的提高、生育年龄的变化趋势以及公共卫生政策的支持。技术进步和长效可逆避孕方法（LARCs）安全性的提升增强了消费者的信心。此外，电子商务平台和远端医疗咨询也提高了产品的可近性和隐私保护水准。

前景依然强劲，非荷尔蒙避孕药和男性避孕药的持续发展将推动市场进一步成长。新兴地区生殖权利意识的提高和医疗保健资金的增加将促进市场进一步成长。然而，监管、文化和伦理因素可能会影响特定国家的市场动态。整体而言，对有效便捷避孕方法的持续需求是长期成长的基础。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球避孕药市场：依产品划分

• 市场分析、洞察与预测
• 装置
• 保险套（男用和女性用）
• 子宫内避孕器（含激素子宫内避孕器、含铜子宫内避孕器）
• 阴道环
• 植入式避孕器
• 隔膜
• 避孕海绵
• 製药
• 口服避孕药
• 注射式避孕药
• 局部避孕药

第五章 全球避孕药市场：依年龄组别划分

• 市场分析、洞察与预测
• 15-44岁
• 44岁或以上

第六章 全球避孕药具市场：依通路划分

• 市场分析、洞察与预测
• 零售药房
• 医院药房
• 线上管道
• 其他分销管道

第七章 全球避孕药市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Afaxys Inc
  • Agile Therapeutics
  • Amneal Pharmaceuticals
  • Bayer AG
  • Church & Dwight Co. Inc
  • Cooper Companies
  • Evofem Biosciences
  • HRA Pharma
  • Maxwellia Ltd
  • Mayer Laboratories Inc
  • Mithra Pharmaceuticals
  • Organon & Co

The Contraceptive Market size is expected to reach USD 53.22 Billion in 2034 from USD 29.71 Billion (2025) growing at a CAGR of 6.69% during 2026-2034.

The global contraceptive market has grown steadily due to increasing awareness of family planning, reproductive health initiatives, and government-supported population control programs. Products such as oral contraceptives, condoms, intrauterine devices (IUDs), injectables, and implants are widely used across developed and emerging markets. Expansion of sexual health education and improved access to healthcare services have further driven adoption.

Major growth drivers include rising female workforce participation, delayed parenthood trends, and supportive public health policies. Technological advancements in long-acting reversible contraceptives (LARCs) and improved safety profiles have increased consumer confidence. E-commerce platforms and telehealth consultations have also enhanced product accessibility and privacy.

Future prospects are strong, with continued innovation in non-hormonal and male contraceptive options under development. Expansion of reproductive rights awareness and healthcare funding in emerging regions will likely support further growth. However, regulatory, cultural, and ethical considerations may influence market dynamics in certain countries. Overall, sustained demand for effective and convenient birth control methods underpins positive long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Devices
• Condoms (Male, Female)
• Intra-Uterine Devices (Hormonal Iud, Copper Iud)
• Vaginal Rings
• Subdermal Implants
• Diaphragms
• Contraceptive Sponges
• Drugs
• Oral Contraceptive Pills
• Injectable Contraceptives
• Topical Contraceptives

By Age Group

• 15 - 44 Years
• Above 44 Years

By Distribution Channels

• Retail Pharmacies
• Hospital Pharmacies
• Online Channels
• Other Distribution Channels

COMPANIES PROFILED

• Afaxys Inc, Agile Therapeutics, Amneal Pharmaceuticals, Bayer AG, Church Dwight Co Inc, Cooper Companies, Evofem Biosciences, HRA Pharma, Maxwellia Ltd, Mayer Laboratories Inc, Mithra Pharmaceuticals, Organon Co

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CONTRACEPTIVE MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Condoms (Male, Female) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Intra-Uterine Devices (Hormonal Iud, Copper Iud) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Vaginal Rings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Subdermal Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Diaphragms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Contraceptive Sponges Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Oral Contraceptive Pills Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.11. Injectable Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.12. Topical Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CONTRACEPTIVE MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Age Group
• 5.2. 15 - 44 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Above 44 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CONTRACEPTIVE MARKET: BY DISTRIBUTION CHANNELS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channels
• 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CONTRACEPTIVE MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Age Group
  • 7.2.3 By Distribution Channels
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Age Group
  • 7.3.3 By Distribution Channels
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Age Group
  • 7.4.3 By Distribution Channels
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Age Group
  • 7.5.3 By Distribution Channels
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Age Group
  • 7.6.3 By Distribution Channels
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CONTRACEPTIVE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Afaxys Inc
  • 9.2.2 Agile Therapeutics
  • 9.2.3 Amneal Pharmaceuticals
  • 9.2.4 Bayer AG
  • 9.2.5 Church & Dwight Co. Inc
  • 9.2.6 Cooper Companies
  • 9.2.7 Evofem Biosciences
  • 9.2.8 HRA Pharma
  • 9.2.9 Maxwellia Ltd
  • 9.2.10 Mayer Laboratories Inc
  • 9.2.11 Mithra Pharmaceuticals
  • 9.2.12 Organon & Co